NYSE:BSX - Boston Scientific Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$36.56 +0.41 (+1.13 %)
(As of 12/12/2018 07:09 AM ET)
Previous Close$36.15
Today's Range$36.16 - $36.95
52-Week Range$24.79 - $39.44
Volume5.71 million shs
Average Volume7.63 million shs
Market Capitalization$49.10 billion
P/E Ratio29.02
Dividend YieldN/A
Beta0.7
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:BSX
Previous Symbol
CUSIP10113710
Phone508-683-4000

Debt

Debt-to-Equity Ratio0.58
Current Ratio0.78
Quick Ratio0.56

Price-To-Earnings

Trailing P/E Ratio29.02
Forward P/E Ratio26.30
P/E Growth2.33

Sales & Book Value

Annual Sales$9.05 billion
Price / Sales5.59
Cash Flow$1.9519 per share
Price / Cash Flow18.73
Book Value$5.11 per share
Price / Book7.15

Profitability

EPS (Most Recent Fiscal Year)$1.26
Net Income$105 million
Net Margins6.93%
Return on Equity26.44%
Return on Assets10.16%

Miscellaneous

Employees29,000
Outstanding Shares1,383,800,000
Market Cap$49.10 billion
OptionableOptionable

Boston Scientific (NYSE:BSX) Frequently Asked Questions

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) released its quarterly earnings results on Wednesday, October, 24th. The medical equipment provider reported $0.35 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.01. The medical equipment provider earned $2.39 billion during the quarter, compared to the consensus estimate of $2.40 billion. Boston Scientific had a net margin of 6.93% and a return on equity of 26.44%. The firm's quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.31 earnings per share. View Boston Scientific's Earnings History.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific issued an update on its FY18 earnings guidance on Wednesday, October, 24th. The company provided earnings per share (EPS) guidance of $1.38-1.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.40. The company issued revenue guidance of $9.787-9.827 billion, compared to the consensus revenue estimate of $9.84 billion.Boston Scientific also updated its FY 2018 guidance to $1.38-1.40 EPS.

What price target have analysts set for BSX?

25 brokerages have issued twelve-month price targets for Boston Scientific's shares. Their forecasts range from $27.00 to $48.00. On average, they anticipate Boston Scientific's stock price to reach $39.76 in the next twelve months. This suggests a possible upside of 8.8% from the stock's current price. View Analyst Price Targets for Boston Scientific.

What is the consensus analysts' recommendation for Boston Scientific?

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 3 hold ratings, 19 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:
  • 1. BTIG Research analysts commented, "Sure Why BSX Buy BSX will acquire BTG plc (BTG-GB, Not Rated) for ~$4B. BTG is in of sales in the U.S. BTG focuses on interventional medicine (oncology and vascular) and also has a pharma division. We are not sure why BSX is trading down ~3%, which is about $1B. This makes little sense to us on a $4B deal. We see the interventional space as a high growth area and oncology/vascular fit within BSX salesforces. BSX has used capital well buying Asthmatx recently. Between this track record and consistently hitting targets, we thought BSX would have leeway with investors to make purchases. BTG’s business OUS, we see this deal as similar to AMS, which has been hugely successful for BSX as it has expanded sales OUS. We feel this deal should benefit BSX’s interventional business like AMMD added growth to urology." (11/21/2018)
  • 2. Needham & Company LLC analysts commented, "BSX announced it is acquiring the private company Augmenix for $500M cash up front and up to $100M in milestones. Augmenix’s SpaceOAR reduces side effects associated with prostate radiotherapy. BSX expects the deal to be immaterial to its adjusted EPS through 2019 and increasingly accretive beginning in 2020. The SpaceOAR hydrogel is CE Marked and FDA cleared and serves an estimated $750M market. We expect the deal to strengthen BSX’s Urology & Pelvic Health business. We expect BSX’s string of acquisitions in 2018 (including Augmenix) to combine to provide a material benefit to its longer-term organic growth and we reiterate our Strong Buy rating and raise our price target to $43 from $39." (9/7/2018)
  • 3. According to Zacks Investment Research, "Boston Scientific's delay in the relaunch of the Lotus range of heart devices is expected to hamper sales in 2018 too. We are also concerned about the declining worldwide pacemaker sales hurting Boston Scientific’s CRM business. A competitive market also adds to the woes. However, the company has been gaining from impressive growth across all its business lines and geographies. The 2018 view also paints a bright picture for the near term. Boston Scientific achieved clinical milestones for Ranger Drug Coated Balloon and WATCHMAN Left Atrial Appendage Closure device. Also, post the suspension of Lotus valve in Europe, ACURATE TAVR valve platform continues to build momentum. Lately, the company announced several strategic acquisitions including NxThera and nVision in Urology and Pelvic Health, EmCision in Endoscopy, Securus in EP and Millipede in Structural Heart. Overall, Boston Scientific outperformed its industry in a year’s time." (7/17/2018)

Has Boston Scientific been receiving favorable news coverage?

Headlines about BSX stock have trended somewhat negative recently, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Boston Scientific earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned media stories about the medical equipment provider a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the next several days.

Who are some of Boston Scientific's key competitors?

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the folowing people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 53)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 52)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 54)
  • Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 45)
  • Mr. Edward F. Mackey, Exec. VP of Operations (Age 55)

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (11.94%), BlackRock Inc. (8.12%), Vanguard Group Inc. (7.33%), Capital World Investors (6.49%), Primecap Management Co. CA (3.24%) and Janus Henderson Group PLC (2.91%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun, Wendy Carruthers, Xin Warren Wang and Yoshiaki Fujimori. View Institutional Ownership Trends for Boston Scientific.

Which institutional investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Deutsche Bank AG, TIAA CREF Investment Management LLC, Putnam Investments LLC, Standard Life Aberdeen plc, Bank of New York Mellon Corp, Mitsubishi UFJ Trust & Banking Corp and Marshall Wace North America L.P.. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Wendy Carruthers, Xin Warren Wang and Yoshiaki Fujimori. View Insider Buying and Selling for Boston Scientific.

Which institutional investors are buying Boston Scientific stock?

BSX stock was purchased by a variety of institutional investors in the last quarter, including Capital Research Global Investors, FMR LLC, Massachusetts Financial Services Co. MA, BlackRock Inc., MARSHALL WACE ASIA Ltd, Point72 Asset Management L.P., Epoch Investment Partners Inc. and Vanguard Group Inc.. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $36.56.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $49.10 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.

What is Boston Scientific's official website?

The official website for Boston Scientific is http://www.bostonscientific.com.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]


MarketBeat Community Rating for Boston Scientific (NYSE BSX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  731 (Vote Outperform)
Underperform Votes:  636 (Vote Underperform)
Total Votes:  1,367
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2018 by MarketBeat.com Staff

Featured Article: Investing in Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel